ALVO
Alvotech
ALVO's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ALVO overall, supported by stronger fundamentals and lower modeled downside.
ALVO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Weak |
ALVO's revenue, profitability, cash flow and balance sheet are all currently under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALVO PE Valuation
ALVO has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 19x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ALVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect ALVO to return to profit, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ALVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.25 | — |
| Q2 2026 | -$0.63 | -432% |
| Q1 2026 | -$0.34 | -200% |
| Q4 2025 | $0.00 | +$0.83 |
| Q3 2025 | $0.21 | +$1.86 |
| Q3 2024 | -$1.65 | +$0.56 |
| Q1 2021 | -$4.90 | -$4.07 |
| Q4 2020 | -$0.69 | +$0.19 |
ALVO has swung to a loss: it lost $0.63 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ALVO on earnings quality, reporting a profit while its opponent remains loss making.
ALVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $105.8M | -39% |
| Q1 2026 | $105.9M | -20% |
| Q4 2025 | $166.4M | +10% |
| Q3 2025 | $114M | +11% |
| Q2 2025 | $173.2M | -13% |
| Q1 2025 | $132.8M | +260% |
| Q4 2024 | $151.2M | +183% |
| Q3 2024 | $102.9M | +478% |
ALVO's revenue has slid since its 2024 peak: $106M last quarter, down 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11% | -22 points |
| Q1 2026 | 9.1% | +1.1 points |
| Q4 2025 | 29% | +20 points |
| Q3 2025 | 1.2% | -11 points |
| Q2 2025 | 10% | -36 points |
| Q1 2025 | 8% | +139 points |
| Q4 2024 | 8.9% | +157 points |
| Q3 2024 | 12% | +511 points |
ALVO's operating margin was −11% last quarter, down 22 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ALVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ALVO on profitability, with a higher operating margin.
ALVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$47.7M | -213% |
| Q1 2026 | -$106.6M | -$95.8M |
| Q4 2025 | -$71.5M | -$1.2M |
| Q3 2025 | -$74.5M | +$11M |
| Q2 2025 | $42.1M | +$99.8M |
| Q1 2025 | -$10.8M | +$69.2M |
| Q4 2024 | -$70.3M | +$7.4M |
| Q3 2024 | -$85.5M | +$38.4M |
ALVO has burned cash in almost every quarter: −$300M over the past year, against −$124M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ALVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +26.5M shares |
| 1 year | +14% | +43.4M shares |
| 3 years | +56% | +128M shares |
| 5 years | +1042% | +326M shares |
| Available history | +46% | +113M shares |
ALVO has 357M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ALVO hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ALVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ALVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 200.4x | High |
| Q1 2026 | 23.3x | High |
| Q4 2025 | 8.8x | High |
| Q3 2025 | 11.3x | High |
| Q2 2025 | 5.4x | High |
| Q1 2025 | 8.6x | High |
| Q3 2022 | 8.1x | High |
ALVO's net debt is more than 20 years of its operating earnings (EBITDA), up from 5.4 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ALVO on leverage, with a lower net debt burden relative to earnings.
ALVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.9 | Neutral |
| Stochastic | 40.7 | Neutral |
ALVO's weekly RSI is 50 (neutral) and its Stochastic is 41 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ALVO PE vs Healthcare Sector
| Metric | ALVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ALVO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ALVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.09 | 8.3% below |
| 20 week MA | $4.60 | 1.5% above |
| 50 week MA | $4.33 | 7.9% above |
| 100 week MA | $6.96 | 33% below |
| 200 week MA | $9.28 | 50% below |
ALVO's trend is mixed: it's above two of its five weekly moving averages, and 50% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ALVO on trend strength, trading above more of its moving averages.
ALVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $9.70 | $10.0 | +3.1% |
| 2023 | $10.0 | $11.5 | +15% |
| 2024 | $11.5 | $12.7 | +10% |
| 2025 | $12.7 | $5.26 | -58% |
| 2026 YTD | $5.26 | $4.67 | -11% |
ALVO has finished higher in three of the last four years. It's down 11% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ALVO on returns for 2026, with the stronger performance.